Compare MPV & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPV | INO |
|---|---|---|
| Founded | 1988 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.4M | 167.5M |
| IPO Year | N/A | 1999 |
| Metric | MPV | INO |
|---|---|---|
| Price | $16.89 | $1.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 9.1K | ★ 17.9M |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 8.71% | N/A |
| EPS Growth | N/A | ★ 54.18 |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | ★ $42,220,086.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.70 | ★ N/A |
| Revenue Growth | N/A | ★ 19.37 |
| 52 Week Low | $15.05 | $0.56 |
| 52 Week High | $20.24 | $2.72 |
| Indicator | MPV | INO |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 55.86 |
| Support Level | $16.14 | $1.08 |
| Resistance Level | $17.33 | $1.94 |
| Average True Range (ATR) | 0.46 | 0.24 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 72.11 | 54.03 |
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.